{
    "clinical_study": {
        "@rank": "19928", 
        "arm_group": [
            {
                "arm_group_label": "PartA: Candesartan, Candesartan + Amolodipine", 
                "arm_group_type": "Active Comparator", 
                "description": "Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally"
            }, 
            {
                "arm_group_label": "PartB: Amlodipine, Amlodipine+Candesartan", 
                "arm_group_type": "Active Comparator", 
                "description": "Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally"
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical trial to evalate the pharmacokinetic interactions and safety between single dose of\n      amlodipine10mg and candesartan32mg and combiation dose amlodipine10mg with candesartan32mg\n      in healthy male volunteers."
        }, 
        "brief_title": "Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male, Age 20 to 45\n\n          2. Subject must be willing and able to provide written informed consent to the study.\n\n        Exclusion Criteria:\n\n          1. History of any significant sickness, liver system, gall bladder system, kidney, nerve\n             system, respiratory system, blood tumor, endocrine system, urinary system, mental\n             disease, muscloskeletal system, immunity system, the ear, nose and throat system and\n             cardiovascular system.\n\n          2. History of  any significant gastrointestinal system and surgery of gastrointestinal.\n\n          3. History of any significant hypersensitivity to amlodipine, candesartan, aspirin,\n             antibiotic.\n\n          4. Over 10 tobaccos a day.\n\n          5. Other condition which in the opinion of the investigator preclude endrollment into\n             the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806311", 
            "org_study_id": "HAMCAO12I_1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PartA: Candesartan, Candesartan + Amolodipine", 
                    "PartB: Amlodipine, Amlodipine+Candesartan"
                ], 
                "intervention_name": "Candesartan32mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "PartA: Candesartan, Candesartan + Amolodipine", 
                    "PartB: Amlodipine, Amlodipine+Candesartan"
                ], 
                "intervention_name": "Amlodipine10mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Candesartan", 
                "Candesartan cilexetil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "Safety", 
            "Male"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daejeon", 
                    "country": "Korea, Republic of", 
                    "state": "Chungcheongbul-do", 
                    "zip": "301-721"
                }, 
                "name": "Chungnam national university hospital,clinical trial center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Chungnam national university hospital, Clinical trial center", 
            "last_name": "Jang Hee Hong, Associate Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Part A : AUC, Cmax of Candesartan", 
                "safety_issue": "Yes", 
                "time_frame": "Over a 24-hour sampling period"
            }, 
            {
                "measure": "Par B : AUC, Cmax of Amlodipine", 
                "safety_issue": "Yes", 
                "time_frame": "Over a 24-hour sampling period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806311"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PartA: Cmin, tmax, CL/F of Candesartan", 
                "safety_issue": "No", 
                "time_frame": "Over a 24-hour sampling period"
            }, 
            {
                "measure": "PartB: Cmin, tmax, CL/F of Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "Over a 24-hour sampling period"
            }
        ], 
        "source": "HanAll BioPharma Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HanAll BioPharma Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}